Floatz logo

(S)-3,5-DICHLORO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-6-HYDROXY-O-ANISAMIDE

Alzheimer Disease

Sunnybrook Health Sciences CentreSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

204 Active assets in the Alzheimer Disease cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Eli Radiopharma
Phase 4BBB
Florbetaben
National Institute of Mental Health (NIMH)
Phase 4BBB
Galantamine Hydrobromide
Janssen Cilag Pharmaceutica S.A.C.I., Greece
Phase 4BBB
Donanemab
Michael Rafii, MD, PhD
Phase 4BB
AMILOMOTIDE
Novartis Pharmaceuticals
Phase 2/3BB

View all 50 →

Same molecule, other indications

(S)-3,5-DICHLORO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-6-HYDROXY-O-ANISAMIDE is also rated in:

AnhedoniaDormant
BB
Indicative ·
65 / 100
View asset →
Major DepressionDormant
BB
Indicative ·
65 / 100
View asset →
DementiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →